Respiratory Vaccines May Reduce Cardiovascular Disease Risk

The European Union is at a crossroads in its approach to public health, with recent developments highlighting both progress and gaps. In early 2026, measles reappeared in six countries that had previously eradicated the disease, raising alarms among health officials. Meanwhile, the European Commission announced a €225 million investment in next-generation flu vaccines designed to combat a broader range of variants and adapt swiftly to emerging threats. These vaccines, which could be administered more easily, represent a step forward in pandemic preparedness.

Separately, the European Medicines Agency approved the first combined vaccine for people aged 50 and older, offering dual protection against seasonal flu and COVID-19. This innovation reflects growing recognition of the need for integrated solutions in immunisation. However, a draft EU cardiovascular disease strategy, currently under debate in the European Parliament, omits any mention of vaccination’s role in preventing heart conditions. This oversight contrasts with the EU Safe Hearts Plan, which explicitly links respiratory infection vaccines to CVD prevention.

Activists and health advocates are pushing for change. On 18 March, the Active Citizenship Network hosted an event in Brussels titled “Council recommendation on the value of immunisation against respiratory infections: a step towards an EU Respiratory Health Plan.” The gathering aimed to highlight the gap in the draft strategy and align with the EU Safe Hearts Plan’s framework. Organisers urged lawmakers to consider input from scientific groups, patient advocates, and industry stakeholders.

The event, supported by the MEPs Interest Group on Patients’ Rights, brought together experts and EU officials. It was part of the “Advancing Respiratory Care at the EU Level” project, funded by Pfizer. Attendees included members of the Steering Group on Prevention of Respiratory Infections, which has proposed amendments based on its manifesto. A parallel “Call to Action” from the EU Working Group on Respiratory Care emphasized the need for a unified approach to respiratory health across the bloc.

MEPs are set to vote on the cardiovascular strategy in June, and the timing of the event has drawn attention. Critics argue that neglecting vaccination’s preventive role risks undermining broader health goals. Some experts note that respiratory infections, including flu and pneumonia, are known to exacerbate heart conditions, yet this link remains underemphasised in policy discussions. The European Parliament’s SANT Committee, which drafted the strategy, has not yet addressed these concerns in its report.

Stakeholders stress that integrating vaccination into CVD prevention is both practical and cost-effective. A 2024 study in the the outlet found that flu vaccination reduced hospitalisations for heart failure by 12% in high-risk groups. Similar findings for pneumonia vaccines suggest a clear public health benefit. Despite this, the draft strategy does not include specific recommendations for expanding immunisation programmes.

The omission has sparked quiet frustration among health professionals. “Vaccines are a cornerstone of preventive care,” said one epidemiologist involved in the event. “Ignoring their role in CVD prevention is a missed opportunity.” As debates continue, the pressure on MEPs to revise the strategy grows. With registration open for the Brussels event, advocates hope the discussion will influence the final document before it reaches a vote.